NO742713L - - Google Patents

Info

Publication number: NO742713L
Authority: NO; Norway
Prior art keywords: radical; carbon atoms; stated; acid derivative; trans
Prior art date: 1973-08-02

Application number

NO742713A

Other languages

English (en)

Norwegian (no)

Inventor

J Bowler

Original Assignee

Ici Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1973-08-02

Filing date

1974-07-25

Publication date

1975-03-03

1974-07-25 Application filed by Ici Ltd filed Critical Ici Ltd

1975-03-03 Publication of NO742713L publication Critical patent/NO742713L/no

Links

-1 alkoxycarbonyl radical Chemical class 0.000 claims description 219
150000001875 compounds Chemical class 0.000 claims description 66
125000004432 carbon atom Chemical group C* 0.000 claims description 60
239000002253 acid Substances 0.000 claims description 42
150000003254 radicals Chemical class 0.000 claims description 30
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
238000002360 preparation method Methods 0.000 claims description 28
239000000203 mixture Substances 0.000 claims description 25
239000002585 base Substances 0.000 claims description 21
238000000034 method Methods 0.000 claims description 18
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
229910052799 carbon Inorganic materials 0.000 claims description 14
ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical compound O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims description 14
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 10
150000003839 salts Chemical class 0.000 claims description 10
239000005977 Ethylene Substances 0.000 claims description 7
150000001350 alkyl halides Chemical class 0.000 claims description 7
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
150000002148 esters Chemical class 0.000 claims description 7
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
125000003545 alkoxy group Chemical group 0.000 claims description 6
125000004849 alkoxymethyl group Chemical group 0.000 claims description 6
125000002947 alkylene group Chemical group 0.000 claims description 6
150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 6
125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 6
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
239000000725 suspension Substances 0.000 claims description 6
125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 5
HSFWRNGVRCDJHI-UHFFFAOYSA-N Acetylene Chemical group C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 4
150000008064 anhydrides Chemical class 0.000 claims description 4
CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 4
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 4
125000006239 protecting group Chemical group 0.000 claims description 4
QOOQLKSEGVNYLA-UHFFFAOYSA-N 1-$l^{1}-oxidanylbutane Chemical compound CCCC[O] QOOQLKSEGVNYLA-UHFFFAOYSA-N 0.000 claims description 3
CPVNCBJFUQQXSU-UHFFFAOYSA-N 5-triphenylphosphaniumylpentanoate Chemical class C1(=CC=CC=C1)[P+](CCCCC(=O)[O-])(C1=CC=CC=C1)C1=CC=CC=C1 CPVNCBJFUQQXSU-UHFFFAOYSA-N 0.000 claims description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
125000003342 alkenyl group Chemical group 0.000 claims description 3
125000000217 alkyl group Chemical group 0.000 claims description 3
229910052801 chlorine Inorganic materials 0.000 claims description 3
125000001309 chloro group Chemical group Cl* 0.000 claims description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
125000005699 methyleneoxy group Chemical group [H]C([H])([*:1])O[*:2] 0.000 claims description 3
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 3
229910052708 sodium Inorganic materials 0.000 claims description 3
239000011734 sodium Substances 0.000 claims description 3
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 2
125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 2
125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 2
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 2
125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
239000000443 aerosol Substances 0.000 claims description 2
229910052783 alkali metal Inorganic materials 0.000 claims description 2
125000005210 alkyl ammonium group Chemical group 0.000 claims description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
229910052794 bromium Inorganic materials 0.000 claims description 2
239000002775 capsule Substances 0.000 claims description 2
239000000460 chlorine Substances 0.000 claims description 2
125000004965 chloroalkyl group Chemical group 0.000 claims description 2
FNLYVHPPASFNNC-UHFFFAOYSA-N chlorocyclohexatriene Chemical compound ClC1=C[C]=CC=C1 FNLYVHPPASFNNC-UHFFFAOYSA-N 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
125000001153 fluoro group Chemical group F* 0.000 claims description 2
125000001207 fluorophenyl group Chemical group 0.000 claims description 2
125000001188 haloalkyl group Chemical group 0.000 claims description 2
125000005843 halogen group Chemical group 0.000 claims description 2
229910052987 metal hydride Inorganic materials 0.000 claims description 2
150000004681 metal hydrides Chemical class 0.000 claims description 2
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 2
125000004430 oxygen atom Chemical group O* 0.000 claims description 2
239000000829 suppository Substances 0.000 claims description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
125000003944 tolyl group Chemical group 0.000 claims description 2
ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 claims description 2
125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims description 2
125000005023 xylyl group Chemical group 0.000 claims description 2
150000001721 carbon Chemical group 0.000 claims 7
JZSAROMFCRBUBD-UHFFFAOYSA-N [O]c1cccc(Cl)c1 Chemical compound [O]c1cccc(Cl)c1 JZSAROMFCRBUBD-UHFFFAOYSA-N 0.000 claims 1
125000005336 allyloxy group Chemical group 0.000 claims 1
125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims 1
125000001624 naphthyl group Chemical group 0.000 claims 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 69
239000000243 solution Substances 0.000 description 21
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
239000002904 solvent Substances 0.000 description 18
239000007858 starting material Substances 0.000 description 17
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 10
239000007983 Tris buffer Substances 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical class CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 7
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
125000003118 aryl group Chemical group 0.000 description 7
238000001819 mass spectrum Methods 0.000 description 7
239000000047 product Substances 0.000 description 7
239000012312 sodium hydride Substances 0.000 description 7
229910000104 sodium hydride Inorganic materials 0.000 description 7
HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical compound O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 6
NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 6
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
230000007062 hydrolysis Effects 0.000 description 5
238000006460 hydrolysis reaction Methods 0.000 description 5
150000004702 methyl esters Chemical class 0.000 description 5
239000000741 silica gel Substances 0.000 description 5
229910002027 silica gel Inorganic materials 0.000 description 5
238000004809 thin layer chromatography Methods 0.000 description 5
HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
150000002576 ketones Chemical class 0.000 description 4
PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
150000001351 alkyl iodides Chemical class 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
150000002596 lactones Chemical class 0.000 description 3
239000012280 lithium aluminium hydride Substances 0.000 description 3
230000003529 luteolytic effect Effects 0.000 description 3
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 3
239000012074 organic phase Substances 0.000 description 3
229910001923 silver oxide Inorganic materials 0.000 description 3
125000001424 substituent group Chemical group 0.000 description 3
MLOSJPZSZWUDSK-UHFFFAOYSA-N 4-carboxybutyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCC(=O)O)C1=CC=CC=C1 MLOSJPZSZWUDSK-UHFFFAOYSA-N 0.000 description 2
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
239000003810 Jones reagent Substances 0.000 description 2
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 2
101800000989 Oxytocin Proteins 0.000 description 2
102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
SMZOGRDCAXLAAR-UHFFFAOYSA-N aluminium isopropoxide Chemical compound [Al+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] SMZOGRDCAXLAAR-UHFFFAOYSA-N 0.000 description 2
150000005840 aryl radicals Chemical class 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
229910000397 disodium phosphate Inorganic materials 0.000 description 2
235000019800 disodium phosphate Nutrition 0.000 description 2
239000003814 drug Substances 0.000 description 2
150000002085 enols Chemical class 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
150000004820 halides Chemical class 0.000 description 2
150000004678 hydrides Chemical class 0.000 description 2
230000009027 insemination Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
150000005217 methyl ethers Chemical class 0.000 description 2
230000027758 ovulation cycle Effects 0.000 description 2
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 2
229960001723 oxytocin Drugs 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
210000002460 smooth muscle Anatomy 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
235000011008 sodium phosphates Nutrition 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
208000009079 Bronchial Spasm Diseases 0.000 description 1
208000014181 Bronchial disease Diseases 0.000 description 1
206010006482 Bronchospasm Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
241000282887 Suidae Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
CYAYKKUWALRRPA-RQICVUQASA-N [(2r,3r,4s,5r)-3,4,5-triacetyloxy-6-bromooxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1OC(Br)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O CYAYKKUWALRRPA-RQICVUQASA-N 0.000 description 1
FCVHBUFELUXTLR-UHFFFAOYSA-N [Li].[AlH3] Chemical compound [Li].[AlH3] FCVHBUFELUXTLR-UHFFFAOYSA-N 0.000 description 1
206010000210 abortion Diseases 0.000 description 1
231100000176 abortion Toxicity 0.000 description 1
125000004036 acetal group Chemical group 0.000 description 1
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
239000003708 ampul Substances 0.000 description 1
239000002269 analeptic agent Substances 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
238000010533 azeotropic distillation Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
125000004799 bromophenyl group Chemical group 0.000 description 1
QNRMTGGDHLBXQZ-UHFFFAOYSA-N buta-1,2-diene Chemical group CC=C=C QNRMTGGDHLBXQZ-UHFFFAOYSA-N 0.000 description 1
KMGBZBJJOKUPIA-UHFFFAOYSA-N butyl iodide Chemical compound CCCCI KMGBZBJJOKUPIA-UHFFFAOYSA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
229960004407 chorionic gonadotrophin Drugs 0.000 description 1
KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
229940124558 contraceptive agent Drugs 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
150000001940 cyclopentanes Chemical class 0.000 description 1
XCIXKGXIYUWCLL-HOSYLAQJSA-N cyclopentanol Chemical class O[13CH]1CCCC1 XCIXKGXIYUWCLL-HOSYLAQJSA-N 0.000 description 1
CSCPPACGZOOCGX-WFGJKAKNSA-N deuterated acetone Substances [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
NKDDWNXOKDWJAK-UHFFFAOYSA-N dimethoxymethane Chemical compound COCOC NKDDWNXOKDWJAK-UHFFFAOYSA-N 0.000 description 1
239000003480 eluent Substances 0.000 description 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
125000004464 hydroxyphenyl group Chemical group 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
244000144972 livestock Species 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000006140 methanolysis reaction Methods 0.000 description 1
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
QOWOXBFFQOXPHM-UHFFFAOYSA-O oxo-[[1-[[4-(oxoazaniumylmethylidene)pyridin-1-yl]methyl]pyridin-4-ylidene]methyl]azanium;chloride Chemical class [Cl-].C1=CC(=C[NH+]=O)C=CN1CN1C=CC(=C[NH+]=O)C=C1 QOWOXBFFQOXPHM-UHFFFAOYSA-O 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000013618 particulate matter Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
125000005767 propoxymethyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])[#8]C([H])([H])* 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
229960004509 serum gonadotrophin Drugs 0.000 description 1
229910001961 silver nitrate Inorganic materials 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
CWXOAQXKPAENDI-UHFFFAOYSA-N sodium methylsulfinylmethylide Chemical compound [Na+].CS([CH2-])=O CWXOAQXKPAENDI-UHFFFAOYSA-N 0.000 description 1
GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000003107 substituted aryl group Chemical group 0.000 description 1
125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Crystallography & Structural Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO742713A 1973-08-02 1974-07-25 NO742713L (xx)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB3669173A GB1451798A (en)	1973-08-02	1973-08-02	Prostanoic acid derivatives

Publications (1)

Publication Number	Publication Date
NO742713L true NO742713L (xx)	1975-03-03

Family

ID=10390378

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO742713A NO742713L (xx)	1973-08-02	1974-07-25

Country Status (24)

Country	Link
US (1)	US3954881A (xx)
JP (1)	JPS5069045A (xx)
AR (1)	AR204013A1 (xx)
AT (1)	AT341119B (xx)
BE (1)	BE818396A (xx)
CH (1)	CH605511A5 (xx)
CS (1)	CS174785B2 (xx)
DD (1)	DD114401A5 (xx)
DE (1)	DE2437388A1 (xx)
DK (1)	DK410174A (xx)
EG (1)	EG11489A (xx)
ES (1)	ES428889A1 (xx)
FI (1)	FI232274A (xx)
FR (1)	FR2239995B1 (xx)
GB (1)	GB1451798A (xx)
IE (1)	IE40157B1 (xx)
IL (1)	IL45299A (xx)
IN (1)	IN138940B (xx)
LU (1)	LU70639A1 (xx)
NL (1)	NL7410343A (xx)
NO (1)	NO742713L (xx)
SE (1)	SE7409930L (xx)
ZA (1)	ZA744509B (xx)
ZM (1)	ZM12074A1 (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1468830A (en) *	1974-01-26	1977-03-30	May & Baker Ltd	Cyclopentane derivatives
US4183870A (en) *	1974-01-26	1980-01-15	May & Baker Limited	Cyclopentane derivatives
GB1506816A (en) *	1975-03-31	1978-04-12	Upjohn Co	Prostaglandins
NL7605381A (nl) *	1975-05-26	1976-11-30	Schering Ag	Werkwijze voor het bereiden van prostaanderi- vaten en werkwijze voor het bereiden van een geneesmiddel met prostaglandinewerking.
US4388457A (en) *	1982-02-11	1983-06-14	University Patents, Inc.	Phyllanthostatin compounds
AU623764B2 (en) *	1989-03-28	1992-05-21	Abbott Laboratories	Erythromycin derivatives
US5352708A (en) *	1992-09-21	1994-10-04	Allergan, Inc.	Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5510383A (en) *	1993-08-03	1996-04-23	Alcon Laboratories, Inc.	Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US6184250B1 (en)	1993-08-03	2001-02-06	Alcon Laboratories, Inc.	Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
US5721273A (en)	1993-12-15	1998-02-24	Alcon Laboratories, Inc.	Use of certain 9-halo-13,14-dihydroprostaglandins to treat glaucoma and ocular hypertension
ATE237587T1 (de) *	1997-02-10	2003-05-15	Ono Pharmaceutical Co	11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten
JP2005527467A (ja) *	2001-08-29	2005-09-15	ネオーズテクノロジーズ，インコーポレイテッド	新規な合成ガングリオシド誘導体およびその組成物
AU2004236174B2 (en)	2001-10-10	2011-06-02	Novo Nordisk A/S	Glycopegylation methods and proteins/peptides produced by the methods
US7214660B2 (en)	2001-10-10	2007-05-08	Neose Technologies, Inc.	Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en)	2001-10-10	2007-02-06	Neose Technologies, Inc.	Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
WO2005012484A2 (en)	2003-07-25	2005-02-10	Neose Technologies, Inc.	Antibody-toxin conjugates
US20080305992A1 (en)	2003-11-24	2008-12-11	Neose Technologies, Inc.	Glycopegylated erythropoietin
WO2006010143A2 (en)	2004-07-13	2006-01-26	Neose Technologies, Inc.	Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
PL2586456T3 (pl)	2004-10-29	2016-07-29	Ratiopharm Gmbh	Remodeling i glikopegilacja czynnika wzrostu fibroblastów (FGF)
EP1814569A2 (en) *	2004-11-09	2007-08-08	Neose Technologies, Inc.	Glycolipids
WO2006074467A2 (en)	2005-01-10	2006-07-13	Neose Technologies, Inc.	Glycopegylated granulocyte colony stimulating factor
EP2386571B1 (en)	2005-04-08	2016-06-01	ratiopharm GmbH	Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20070105755A1 (en)	2005-10-26	2007-05-10	Neose Technologies, Inc.	One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en)	2005-11-03	2007-05-18	Neose Technologies, Inc.	Nucleotide sugar purification using membranes
US20080280818A1 (en)	2006-07-21	2008-11-13	Neose Technologies, Inc.	Glycosylation of peptides via o-linked glycosylation sequences
US8969532B2 (en)	2006-10-03	2015-03-03	Novo Nordisk A/S	Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
KR20150064246A (ko)	2007-04-03	2015-06-10	바이오제너릭스 게엠베하	글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
US9493499B2 (en)	2007-06-12	2016-11-15	Novo Nordisk A/S	Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
PL2257311T3 (pl)	2008-02-27	2014-09-30	Novo Nordisk As	Koniugaty cząsteczek czynnika VIII
WO2010111530A1 (en)	2009-03-25	2010-09-30	Seneb Biosciences, Inc.	Glycolipids as treatment for disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1334952A (en) *	1971-01-06	1973-10-24	Ici Ltd	Cyclopentane derivat-ves and a process for their manufacture

1973
- 1973-08-02 GB GB3669173A patent/GB1451798A/en not_active Expired
1974
- 1974-01-01 AR AR255032A patent/AR204013A1/es active
- 1974-07-12 IE IE1472/74A patent/IE40157B1/xx unknown
- 1974-07-15 US US05/488,759 patent/US3954881A/en not_active Expired - Lifetime
- 1974-07-15 ZA ZA00744509A patent/ZA744509B/xx unknown
- 1974-07-18 IL IL45299A patent/IL45299A/xx unknown
- 1974-07-18 IN IN1602/CAL/74A patent/IN138940B/en unknown
- 1974-07-23 ZM ZM120/74A patent/ZM12074A1/xx unknown
- 1974-07-25 NO NO742713A patent/NO742713L/no unknown
- 1974-07-31 LU LU70639A patent/LU70639A1/xx unknown
- 1974-07-31 DK DK410174*A patent/DK410174A/da unknown
- 1974-07-31 DD DD180228A patent/DD114401A5/xx unknown
- 1974-07-31 CH CH1055174A patent/CH605511A5/xx not_active IP Right Cessation
- 1974-08-01 SE SE7409930A patent/SE7409930L/xx unknown
- 1974-08-01 FR FR7426759A patent/FR2239995B1/fr not_active Expired
- 1974-08-01 BE BE147209A patent/BE818396A/xx unknown
- 1974-08-01 CS CS5488A patent/CS174785B2/cs unknown
- 1974-08-01 NL NL7410343A patent/NL7410343A/xx not_active Application Discontinuation
- 1974-08-02 ES ES428889A patent/ES428889A1/es not_active Expired
- 1974-08-02 DE DE2437388A patent/DE2437388A1/de not_active Withdrawn
- 1974-08-02 JP JP49088920A patent/JPS5069045A/ja active Pending
- 1974-08-02 AT AT635674A patent/AT341119B/de not_active IP Right Cessation
- 1974-08-02 FI FI2322/74A patent/FI232274A/fi unknown
- 1974-08-03 EG EG316/74A patent/EG11489A/xx active

Also Published As

Publication number	Publication date
DE2437388A1 (de)	1975-02-13
FR2239995A1 (xx)	1975-03-07
IE40157L (en)	1975-02-02
IL45299A (en)	1978-06-15
BE818396A (fr)	1975-02-03
ZA744509B (en)	1975-07-30
ZM12074A1 (en)	1976-11-22
JPS5069045A (xx)	1975-06-09
IE40157B1 (en)	1979-03-28
ES428889A1 (es)	1976-09-01
EG11489A (en)	1978-06-30
AU7163574A (en)	1976-01-29
IN138940B (xx)	1976-04-17
CS174785B2 (xx)	1977-04-29
DD114401A5 (xx)	1975-08-05
LU70639A1 (xx)	1974-12-10
FR2239995B1 (xx)	1978-07-21
GB1451798A (en)	1976-10-06
SE7409930L (xx)	1975-02-03
CH605511A5 (xx)	1978-09-29
DK410174A (xx)	1975-04-01
US3954881A (en)	1976-05-04
ATA635674A (de)	1977-05-15
IL45299A0 (en)	1974-10-22
FI232274A (xx)	1975-02-03
AR204013A1 (es)	1975-11-12
AT341119B (de)	1978-01-25
NL7410343A (nl)	1975-02-04

Publication	Publication Date	Title
NO742713L (xx)	1975-03-03
CA1079725A (en)	1980-06-17	Prostaglandin-acetylene analogues and process for their manufacture
DE2704933A1 (de)	1977-08-18	Prostaglandin-analoga mit dreifachbindung zwischen c-13 und c-14 und verfahren zu ihrer herstellung
SE424636B (sv)	1982-08-02	Analogiforfarande for framstellning av 16-fenoxi- och 16-(o, m eller p)-substituerade fenoxiprosta-4,5,13-triensyraderivat
DK149954B (da)	1986-11-03	Analogifremgangsmaade til fremstilling af 18-umaettede prostacyklinderivater
DE2365035A1 (de)	1974-07-04	Prostaglandin-analoge
DE2317019A1 (de)	1973-11-08	Neue 4,5-didehydro-prostaglandine
NO139521B (no)	1978-12-18	Prostansyrederivat for anvendelse som svangerskapsforebyggende middel, som svangerskapsavbrytende middel, for regulering av den oestrale periode og som tilsetning til saed ved inseminasjon
DE2348632A1 (de)	1974-04-11	Prostansaeurederivate
JPS6021979B2 (ja)	1985-05-30	４，４，５，５―テトラデヒドロｐｇｅ↓１
US4140712A (en)	1979-02-20	20-Hydroxy-prostaglandins
DE2626888A1 (de)	1977-04-07	11-desoxy-16-aryloxy-omega-tetranorprostaglandine
DK145083B (da)	1982-08-23	Prostaglandin-analoge til anvendelse i midler til regulering af den reproduktive cyclos hos raske pattedyr
DK157852B (da)	1990-02-26	Analogifremgangsmaade til fremstilling af prostacyclinderivater
US4154950A (en)	1979-05-15	15-Epi-15-methyl-16-phenoxy-PGE compounds
US4321275A (en)	1982-03-23	Method of inducing luteolysis using 16-aryloxy-17,18,19,20-tetranor-prostanoic acid derivatives
US4306095A (en)	1981-12-15	Prostane derivatives
NO751420L (xx)	1975-10-23
US3835179A (en)	1974-09-10	Novel 15-substituted prostanoic acids and esters
NO752734L (xx)	1976-02-06
US4018804A (en)	1977-04-19	Intermediate for synthesis of Thromboxane B2
US4001300A (en)	1977-01-04	2,2-Difluoro-16-phenoxy-PGF2 analogs
US3974195A (en)	1976-08-10	2A,2B-Dihomo-15-alkyl-PGF2.sub.α analogs
US4020173A (en)	1977-04-26	4α,6-Dihydroxy-2β-carboxaldehyde-3α-tetrahydropyranacetic acid γ-lactone, 6-alkyl ethers
US3894009A (en)	1975-07-08	Prostaglandin derivatives and process for the preparation thereof